Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stockholm - Delayed Quote SEK

PharmaLundensis AB (PHAL.ST)

0.5720
-0.0280
(-4.67%)
At close: April 28 at 4:26:12 PM GMT+2
Loading Chart for PHAL.ST
  • Previous Close 0.6000
  • Open 0.5700
  • Bid 0.5400 x --
  • Ask 0.5720 x --
  • Day's Range 0.5400 - 0.5880
  • 52 Week Range 0.2900 - 1.5200
  • Volume 50,480
  • Avg. Volume 26,941
  • Market Cap (intraday) 30.469M
  • Beta (5Y Monthly) -0.43
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0800
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

PharmaLundensis AB operates as a pharmaceutical company. The company develops Iodocarb for treating chronic obstructive pulmonary disease; and treatments for chronic bronchitis and influenza-induced lung failure. It develops EcoFilter, a system that eliminates the release of pharmaceutical drugs and multi-resistant bacteria in hospital wastewater. PharmaLundensis AB was founded in 2006 and is based in Lund, Sweden.

www.pharmalundensis.se

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PHAL.ST

View More

Performance Overview: PHAL.ST

Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

PHAL.ST
7.74%
OMX Stockholm 30 Index (^OMX)
2.22%

1-Year Return

PHAL.ST
22.07%
OMX Stockholm 30 Index (^OMX)
5.07%

3-Year Return

PHAL.ST
22.34%
OMX Stockholm 30 Index (^OMX)
19.11%

5-Year Return

PHAL.ST
52.78%
OMX Stockholm 30 Index (^OMX)
54.80%

Compare To: PHAL.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHAL.ST

View More

Valuation Measures

Annual
As of 4/28/2025
  • Market Cap

    30.47M

  • Enterprise Value

    34.92M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    9.68

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -19.47%

  • Return on Equity (ttm)

    -119.23%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -3.85M

  • Diluted EPS (ttm)

    -0.0800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.27M

  • Total Debt/Equity (mrq)

    173.41%

  • Levered Free Cash Flow (ttm)

    -4.35M

Research Analysis: PHAL.ST

View More

Company Insights: PHAL.ST

Research Reports: PHAL.ST

View More

People Also Watch